Moderna's Flu Vaccine BLA Receives FDA Refusal-to-File Letter, Delays US Approval

summarizeSummary

Moderna announced the FDA issued a Refusal-to-File letter for its seasonal influenza vaccine, mRNA-1010, due to the comparator choice in its Phase 3 study, delaying U.S. approval but not impacting 2026 financial guidance.

check_boxKey Events · Product Development and Regulatory · MRNA

• FDA Issues Refusal-to-File Letter

  The U.S. Food and Drug Administration (FDA) issued a Refusal-to-File (RTF) letter for Moderna's Biologics License Application (BLA) for its investigational seasonal influenza vaccine, mRNA-1010.

• Reason for Refusal

  The RTF was solely due to the choice of a licensed standard-dose seasonal influenza vaccine comparator in the Phase 3 study, not due to safety or efficacy concerns with mRNA-1010.

• No Impact on 2026 Financial Guidance

  Moderna stated that it does not expect this regulatory setback to impact its previously issued 2026 financial guidance.

• International Regulatory Progress

  mRNA-1010 has been accepted for review in the EU, Canada, and Australia, with submissions planned for additional countries in 2026.

auto_awesomeAnalysis · MRNA · Life Sciences

Moderna received a Refusal-to-File (RTF) letter from the FDA for its investigational seasonal influenza vaccine, mRNA-1010, meaning the agency will not initiate a review of the Biologics License Application (BLA). This is a significant regulatory setback, delaying potential market entry in the U.S. The FDA's decision was solely based on the choice of a licensed standard-dose seasonal influenza vaccine comparator in the Phase 3 study, not on safety or efficacy concerns. Moderna has requested a Type A meeting with the FDA to clarify the path forward. Despite this, the company stated it does not expect any impact on its 2026 financial guidance, which helps mitigate the immediate financial concern. The vaccine has been accepted for review in the EU, Canada, and Australia, indicating progress in other major markets.